Search

Your search keyword '"Gong, Gyungyub"' showing total 822 results
Start Over Author "Gong, Gyungyub"
822 results on '"Gong, Gyungyub"'

4. Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence

Author

Yoo, Tae-Kyung Robyn, Lee, Ji-Young, Park, Hwan, Cho, Whi-Kyung, Jeon, Seyeon, Jun, Ha Ra, Lee, Sae Byul, Chung, Il Yong, Kim, Hee Jeong, Ko, Beom Seok, Lee, Jong Won, Son, Byung Ho, Ahn, Sei-Hyun, Jeong, Jae Ho, Kim, Jeong Eun, Ahn, Jin-Hee, Jung, Kyung Hae, Kim, Sung-Bae, Lee, Hee Jin, Gong, Gyungyub, Kim, Jisun, and Chun, Sung-Min

Published
2024
Full Text
View/download PDF

12. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)

Author

Hwang, Inhwan, Kim, Jeong Eun, Jeong, Jae Ho, Ahn, Jin-Hee, Jung, Kyung Hae, Son, Byung Ho, Kim, Hak Hee, Shin, Junyoung, Lee, Hee Jin, Gong, Gyungyub, and Kim, Sung-Bae

Published
2023
Full Text
View/download PDF

17. Optimal chemokine receptors for enhancing immune cell trafficking in adoptive cell therapy.

Author

Han, DoYeon, Jeong, Byung-Kwan, Hong, Jong Moo, Seo, Jeong-Han, Lee, GunHee, Kim, Kwanghee, Hong, Chorong, Lee, Hyeonjin, Cha, Su Min, Kim, Jong Hyeok, Park, Taehyun, Gong, Gyungyub, and Lee, Hee Jin

Abstract

Recently, a strategy involving the engineering of chemokine receptors on immune cells was developed to optimize adoptive cell therapy (ACT) for solid tumors. Given the variability in chemokine secretion among different tumor types, identifying and modulating the appropriate chemokine receptors is crucial. In this study, we utilized extensive RNA sequencing data from both tumor tissues from The Cancer Genome Atlas and normal tissues from Genotype-Tissue Expression to investigate the expression profiles of chemokines. Through analysis, we identified eight chemokine receptors associated with increased chemokine levels in tumor tissues compared to normal tissues, making them promising candidates for enhancing ACT. Subsequent examination of tumor-infiltrating lymphocytes and chimeric antigen receptor-T cells revealed that five out of the eight candidate chemokine receptors did not exhibit elevated expression in T cells. Among five candidates, we demonstrated that CXCR5 is a particularly promising candidate for enhancing cell migration without compromising cell viability or cytotoxicity. In conclusion, our study underscores the potential of five chemokine receptors (CCR6, CCR9, CXCR1, CXCR5, and XCR1) as valuable targets for modulating ACT to enhance cell trafficking and potentially improve cancer therapy outcomes. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

30. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Author

Bossuyt, V, Provenzano, E, Symmans, WF, Boughey, JC, Coles, C, Curigliano, G, Dixon, JM, Esserman, LJ, Fastner, G, Kuehn, T, Peintinger, F, von Minckwitz, G, White, J, Yang, W, Badve, S, Denkert, C, MacGrogan, G, Penault-Llorca, F, Viale, G, Cameron, D, collaboration, Breast International Group-North American Breast Cancer Group, Earl, Helena, Alba, Emilio, Lluch, Ana, Albanell, Joan, Amos, Keith, Biernat, Wojciech, Bonnefoi, Hervé, Buzdar, Aman, Cane, Paul, Pinder, Sarah, Carson, Lesley, Dickson-Witmer, Diana, Gong, Gyungyub, Green, Jimmy, Hsu, Chih-Yi, Tseng, Ling-Ming, Kroep, Judith, Leitch, A Marilyn, Sarode, Venetia, Mamounas, Eleftherios, Marcom, Paul Kelly, Nuciforo, Paolo, Paik, Soonmyung, Peg, Vicente, Peston, David, Pierga, Jean-Yves, Quintela-Fandino, Miguel, Salgado, Roberto, Sikov, William, Thomas, Jeremy, Unzeitig, Gary, and Wesseling, Jelle

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Breast Cancer, Cancer, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Clinical Trials as Topic, Female, Humans, Neoadjuvant Therapy, Neoplasm Staging, Neoplasm, Residual, Practice Guidelines as Topic, Prognosis, breast cancer, neoadjuvant systemic therapy, residual disease, pathologic complete response, pathologic assessment, response evaluation, Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow-up. However, significant variability exists in methods of pathologic assessment of response to NAST, and thus its interpretation for subsequent clinical decisions. Our international multidisciplinary working group was convened by the Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration and tasked to recommend practical methods for standardized evaluation of the post-NAST surgical breast cancer specimen for clinical trials that promote accurate and reliable designation of pathologic complete response (pCR) and meaningful characterization of residual disease. Recommendations include multidisciplinary communication; clinical marking of the tumor site (clips); and radiologic, photographic, or pictorial imaging of the sliced specimen, to map the tissue sections and reconcile macroscopic and microscopic findings. The information required to define pCR (ypT0/is ypN0 or ypT0 yp N0), residual ypT and ypN stage using the current AJCC/UICC system, and the Residual Cancer Burden system were recommended for quantification of residual disease in clinical trials.

Published
2015

34. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy

Author

Masuda, Hiroko, Harano, Kenichi, Miura, Sakiko, Wang, Ying, Hirota, Yuko, Harada, Oi, Jolly, Mohit Kumar, Matsunaga, Yuki, Lim, Bora, Wood, Anita L., Parinyanitikul, Napa, Jin Lee, Hee, Gong, Gyungyub, George, Jason T., Levine, Herbert, Lee, Jangsoon, Wang, Xiaoping, Lucci, Anthony, Rao, Arvind, Schweitzer, Brock L., Lawrence, O. Rayne, Seitz, Robert S., Morris, Stephan W., Hout, David R., Nakamura, Seigo, Krishnamurthy, Savitri, and Ueno, Naoto T.

Published
2022
Full Text
View/download PDF

35. Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study

Author

Chae, Sun Young, Ahn, Sei Hyun, Kim, Sung-Bae, Han, Sangwon, Lee, Suk Hyun, Oh, Seung Jun, Lee, Sang Ju, Kim, Hee Jeong, Ko, Beom Seok, Lee, Jong Won, Son, Byung Ho, Kim, Jisun, Ahn, Jin-Hee, Jung, Kyung Hae, Kim, Jeong Eun, Kim, Seog-Young, Choi, Woo Jung, Shin, Hee Jung, Gong, Gyungyub, Lee, Hyo Sang, Lee, Jung Bok, and Moon, Dae Hyuk

Published
2019
Full Text
View/download PDF

36. Improved Diagnostic Accuracy of Thyroid Fine-Needle Aspiration Cytology with Artificial Intelligence Technology.

Author

Lee, Yujin, Alam, Mohammad Rizwan, Park, Hongsik, Yim, Kwangil, Seo, Kyung Jin, Hwang, Gisu, Kim, Dahyeon, Chung, Yeonsoo, Gong, Gyungyub, Cho, Nam Hoon, Yoo, Chong Woo, Chong, Yosep, and Choi, Hyun Joo

Subjects
NEEDLE biopsy, ARTIFICIAL intelligence, CYTOLOGY, QUALITY control, THYROID gland
Abstract

Background: Artificial intelligence (AI) is increasingly being applied in pathology and cytology, showing promising results. We collected a large dataset of whole slide images (WSIs) of thyroid fine-needle aspiration cytology (FNA), incorporating z-stacking, from institutions across the nation to develop an AI model. Methods: We conducted a multicenter retrospective diagnostic accuracy study using thyroid FNA dataset from the Open AI Dataset Project that consists of digitalized images samples collected from 3 university hospitals and 215 Korean institutions through extensive quality check during the case selection, scanning, labeling, and reviewing process. Multiple z-layer images were captured using three different scanners and image patches were extracted from WSIs and resized after focus fusion and color normalization. We pretested six AI models, determining Inception ResNet v2 as the best model using a subset of dataset, and subsequently tested the final model with total datasets. Additionally, we compared the performance of AI and cytopathologists using randomly selected 1031 image patches and reevaluated the cytopathologists' performance after reference to AI results. Results: A total of 10,332 image patches from 306 thyroid FNAs, comprising 78 malignant (papillary thyroid carcinoma) and 228 benign from 86 institutions were used for the AI training. Inception ResNet v2 achieved highest accuracy of 99.7%, 97.7%, and 94.9% for training, validation, and test dataset, respectively (sensitivity 99.9%, 99.6%, and 100% and specificity 99.6%, 96.4%, and 90.4% for training, validation, and test dataset, respectively). In the comparison between AI and human, AI model showed higher accuracy and specificity than the average expert cytopathologists beyond the two-standard deviation (accuracy 99.71% [95% confidence interval (CI), 99.38–100.00%] vs. 88.91% [95% CI, 86.99–90.83%], sensitivity 99.81% [95% CI, 99.54–100.00%] vs. 87.26% [95% CI, 85.22–89.30%], and specificity 99.61% [95% CI, 99.23–99.99%] vs. 90.58% [95% CI, 88.80–92.36%]). Moreover, after referring to the AI results, the performance of all the experts (accuracy 96%, 95%, and 96%, respectively) and the diagnostic agreement (from 0.64 to 0.84) increased. Conclusions: These results suggest that the application of AI technology to thyroid FNA cytology may improve the diagnostic accuracy as well as intra- and inter-observer variability among pathologists. Further confirmatory research is needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer

Author

Fujiki, Yoshitaka, primary, Kashiwaba, Masahiro, additional, Sato, Mutsumi, additional, Kawano, Junko, additional, Teraoka, Megumi, additional, Kanemitsu, Shuichi, additional, Rai, Yoshiaki, additional, Taira, Tetsuhiko, additional, Sagara, Yoshiaki, additional, Ohi, Yasuyo, additional, Jo, Uiree, additional, Lee, Young-Won, additional, Lee, Sae Byul, additional, Gong, Gyungyub, additional, Shin, Young Kee, additional, Kwon, Mi Jeong, additional, and Sagara, Yasuaki, additional

Published
2023
Full Text
View/download PDF

43. 21‐gene expression assay and clinical outcomes of premenopausal patients with hormone receptor‐positive breast cancer

Author

Hyung, Jaewon, primary, Lee, Sae Byul, additional, Kim, Jisun, additional, Kim, Hee Jeong, additional, Ko, BeomSeok, additional, Lee, Jong Won, additional, Son, Byung‐Ho, additional, Lee, Hee Jin, additional, Gong, Gyungyub, additional, Jeong, Hyehyun, additional, Jeong, Jae Ho, additional, Kim, Jeong Eun, additional, Ahn, Jin‐Hee, additional, Jung, Kyung Hae, additional, and Kim, Sung‐Bae, additional

Published
2023
Full Text
View/download PDF

45. Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer

Author

Lee, Janghee, primary, Lee, Young-jin, additional, Bae, Soong June, additional, Baek, Seung Ho, additional, Kook, Yoowon, additional, Cha, Yoon Jin, additional, Lee, Jong Won, additional, Son, Byung Ho, additional, Ahn, Sei Hyun, additional, Lee, Hee Jin, additional, Gong, Gyungyub, additional, Jeong, Joon, additional, Lee, Sae Byul, additional, and Ahn, Sung Gwe, additional

Published
2023
Full Text
View/download PDF

50. 21‐gene expression assay and clinical outcomes of premenopausal patients with hormone receptor‐positive breast cancer.

Author

Hyung, Jaewon, Lee, Sae Byul, Kim, Jisun, Kim, Hee Jeong, Ko, BeomSeok, Lee, Jong Won, Son, Byung‐Ho, Lee, Hee Jin, Gong, Gyungyub, Jeong, Hyehyun, Jeong, Jae Ho, Kim, Jeong Eun, Ahn, Jin‐Hee, Jung, Kyung Hae, and Kim, Sung‐Bae

Subjects
BREAST cancer, TREATMENT effectiveness, MEDICAL centers
Abstract

The prognostic role of the recurrence score (RS) based on the 21‐gene expression assay in premenopausal women is not well delineated, and we investigated the association of outcomes and the RS in premenopausal patients who had 21‐gene expression assay at Asan Medical Center, Seoul, Korea, between June 2005 and July 2018. Invasive breast cancer‐free survival (IBCFS) by STEEP version 2.0 was compared according to the RS and clinical risk factors. A total of 554 patients were included in our study and 116 patients (20.9%) had age <40 years, 238 patients (43.0%) had luminal B subtype (Ki67 ≥ 20%), and 83 patients (15.0%) had RS >25. All patients received adjuvant tamoxifen ± chemotherapy. Overall, patients with RS >25 showed trend toward worse IBCFS from multivariable analysis (adjusted HR 1.89 [95% CI: 0.95‐3.73], P =.069). When comparing outcomes according to age and luminal subtypes, patients with luminal B subtype and age <40 years (n = 60) showed significantly worse outcomes compared to the others (luminal A or luminal B + age ≥40 years, n = 494; adjusted HR 2.95 [95% CI: 1.49‐5.82], log‐rank P <.001). Among patients with luminal B subtype and age <40 years, there was no significant association observed between IBCFS and the RS (log‐rank P =.51). In conclusion, while RS >25 showed association with poor outcomes in premenopausal women, it may have less prognostic significance among those with luminal B subtype and age <40 years. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results